News | February 21, 2023
Teijin and Axcelead to establish drug discovery research JV
The new company will utilize Teijin's drug discovery research technologies, facilities, equipment and personnel.
The new company will utilize Teijin's drug discovery research technologies, facilities, equipment and personnel.
New subgroup analysis from Phase III ARASENS trial shows that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel increased overall survival (OS)
Agasta Software is engaged in research, development and commercialization of medical devices
Cipla has received 8 inspectional observations in Form 483
Canagliflozin and Metformin Hydrochloride Tablets had annual sales of US $49.4 million in the United States
There is a fast resurgence in the transplant activities post COVID
Fluor is providing architectural and engineering services and procuring equipment for the new 275,000 square-foot manufacturing facility that will house two manufacturing lines to double manufacturing capability
Data build on previously reported results from the primary endpoint of investigator-assessed radiographic progression-free survival
Sirolimus Tablets had annual sales of USD 69 million in the United States (IQVIA MAT Dec. 2022)
The EIR was issued post the last inspection of the facility conducted from October 17, 2022 to October 29, 2022
Subscribe To Our Newsletter & Stay Updated
